Role of Perioperative Immune Checkpoint Inhibitors in Muscle Invasive Bladder Cancer.

ABSTRACT:

Objective

We aim to describe and highlight the current use of immune checkpoint inhibitors (ICIs) in the muscle invasive bladder cancer (MIBC) treatment landscape, particularly focusing on the perioperative setting. We provide a comprehensive review of key trials of the use of ICI in the perioperative setting, discussing trial outcomes and limitations and reviewing the role of biomarkers.

Introduction

ICIs have recently been integrated into the treatment algorithm for metastatic urothelial carcinoma. More than 30 published studies have investigated the role of these agents in the radical treatment of MIBC. Some studies have demonstrated conflicting results, affecting widespread adoption in clinical practice.

Methods

We performed a narrative overview of the literature

SUBMITTER: Chhaya S 

PROVIDER: S-EPMC9935774 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature